Ubs Group Ag Genfit S.A. Call Options Transaction History
Ubs Group Ag
- $452 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding GNFT
# of Institutions
5Shares Held
77.7KCall Options Held
0Put Options Held
0-
Optiver Holding B.V. Amsterdam, P751.8KShares$233,0910.01% of portfolio
-
Morgan Stanley New York, NY25KShares$112,5900.0% of portfolio
-
Rhumbline Advisers Boston, MA678Shares$3,0510.0% of portfolio
-
Advisor Group Holdings, Inc. Phoenix, AZ250Shares$1,1250.0% of portfolio
-
Concourse Financial Group Securities, Inc. Birmingham, AL0Shares$00.0% of portfolio
About Genfit S.A.
- Ticker GNFT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 49,815,500
- Market Cap $224M
- Description
- Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagno...